A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Commentary|Podcasts|July 29, 2025
A Roundtable Discussion of Upcoming Hot Line Trials at ESC Congress 2025
Experts discuss groundbreaking Hot Line trials at the European Society of Cardiology Congress 2025, offering insights into the latest cardiovascular research.
Advertisement
In this episode, Kaitlin Hile, PharmD, BCCP; Robert Page, PharmD, MSPH, BCPS (AQ-cards), BCGP, FAHA, FHFSA, FCCP, FASHP; and Robert DiDomenico, PharmD, FCCP, FHFSA, FACC, sat down with host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-cards), CACP, for an exciting discussion of several Hot Line trials at the upcoming European Society of Cardiology Congress 2025.
Learn more about the ESC Congress 2025 Hot Line
Advertisement
Related to this article
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Advertisement
Advertisement